FDA approves Eversense 365, a year-long CGM for Type 1 and 2 diabetes, with annual insertion.
The FDA has approved the Eversense 365 continuous glucose monitoring (CGM) system, the first device of its kind to last a full year, for adults with Type 1 and Type 2 diabetes. Developed by Senseonics and Ascensia Diabetes Care, it requires only one insertion annually, improving convenience and accuracy. The system is set for commercial release in late 2024 and may integrate with insulin pumps for automated delivery systems.
September 17, 2024
9 Articles